OMCL · Omnicell, Inc.

Omnicell delivered strong Q1 2026 results with total revenues of $310 million, a 15% increase from the prior year, primarily driven by strength in connected devices offerings alongside growth in technical services, SaaS and Expert Services, and consumables. This execution reflects sustained demand for core points of care solutions amid complex care environments, as highlighted by CEO Randall Lipps, who emphasized reliability, efficiency, and standardization in medication workflows. Profitability improved markedly, with GAAP net income swinging to $11 million from a $7 million loss, and non-GAAP metrics showing non-GAAP net income of $25 million and EBITDA of $45 million, more than doubling year-over-year, supported by disciplined cost management. Balance sheet remains solid with $239 million in cash, $168 million net debt, and $350 million revolver availability, while operating cash flow doubled to $55 million. Guidance was raised for full-year 2026, expanding non-GAAP EBITDA to $153-$168 million and EPS to $1.80-$2.00, with total revenues now at $1.215-$1.255 billion, signaling confidence in trajectory. Strategic advancements include customer engagement for Omnicell Titan XT post-ASHP introduction and maturing OmniSphere cloud platform, showcased at AONL and EAHP, positioning for long-term enterprise-wide intelligence and growth. The launch of Omnicell Customer Community further enhances peer collaboration. These results underscore model durability and platform evolution for workflow optimization.